Menu Search
Equities

Liquidia Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LT4:FRA

Liquidia Corp

Actions
  • Price (EUR)35.10
  • Today's Change-1.00 / -2.77%
  • Shares traded114.00
  • 1 Year change+127.92%
  • Beta0.4758
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

  • Revenue in USD (TTM)69.22m
  • Net income in USD-121.85m
  • Incorporated2020
  • Employees157.00
  • Location
    Liquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
  • Phone+1 (919) 328-4400
  • Fax+1 (919) 328-4402
  • Websitehttps://www.liquidia.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.